360iResearch Logo
Global Parkinson's Disease Therapeutics Market
Report Code: MRR-CF3B54E | Publishing Date: July 2020 | Number of Pages: 214

FEATURED COMPANIES

  1. Abbvie, Inc.
  2. ACADIA Pharmaceuticals, Inc.
  3. Amneal Pharmaceuticals, Inc.
  4. Apotex, Inc.
  5. Bausch Health Companies, Inc.
  6. Boehringer Ingelheim International GmbH
  7. Cipla, Inc.
  8. Daiichi Sankyo Company
  9. H. Lundbeck A/S
  10. Mylan N.V.
  11. Novartis AG
  12. Orion Corporation
  13. Par Pharmaceutical by Endo International PLC
  14. Sun Pharmaceutical Industries Limited
  15. Teva Pharmaceutical Industries Ltd.
  16. UCB S.A.
  17. WOCKHARDT

The Global Parkinson's Disease Therapeutics Market to grow from USD 4,985.67 Million in 2019 to USD 7,522.33 Million by 2025, at a Compound Annual Growth Rate (CAGR) of 7.09%.

Market Segmentation & Coverage:

The research report categorizes the Parkinson's Disease Therapeutics Market to forecast the revenues and analyze the trends in each of the following segments:

"The Intestinal Infusion is projected to witness the highest growth during the forecast period"

Based on Type, the Parkinson's Disease Therapeutics Market studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal. The Oral commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Intestinal Infusion. On the other hand, the Intestinal Infusion expected to grow at the fastest CAGR during the forecast period, followed by the Transdermal.

"The Anticholinergic is projected to witness the highest growth during the forecast period"

Based on Drug Class, the Parkinson's Disease Therapeutics Market studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor. The Carbidopa/Levodopa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Anticholinergic. On the other hand, the Anticholinergic expected to grow at the fastest CAGR during the forecast period, followed by the Carbidopa/Levodopa.

"The Online Pharmacy is projected to witness the highest growth during the forecast period"

Based on Distribution Channel, the Parkinson's Disease Therapeutics Market studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy. The Hospital Pharmacy commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Retailer Pharmacy. On the other hand, the Online Pharmacy expected to grow at the fastest CAGR during the forecast period, followed by the Retailer Pharmacy.

"The Clinic is projected to witness the highest growth during the forecast period"

Based on End Use, the Parkinson's Disease Therapeutics Market studied across Clinic and Hospital. The Hospital commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Clinic. On the other hand, the Clinic expected to grow at the fastest CAGR during the forecast period, followed by the Hospital.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

Based on Geography, the Parkinson's Disease Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Americas. On the other hand, the Asia-Pacific expected to grow at the fastest CAGR during the forecast period, followed by the Americas.

Market Dynamics:

The factors attributing to the growth of the market are development of new therapies and minimally invasive new devices and growing aging population and the associated increase in the prevalence of parkinson’s disease. However, some factors such as availability of alternative treatments may hinder the market growth. The Parkinson's Disease Therapeutics Market expected to showcase the opportunities such as potential for pharmaceutical companies due to patent expiry, strong drug pipeline under clinical research, and increasing pace of r&d by the government in the u.s., the uk, and other countries for parkinson's disease management. Soon market may face the possible challenges in the growth due to sales erosion due to expiry of patents. However, the key players in the market are putting regressive efforts to provide innovative offerings and benchmark strategies in the market.

Global Parkinson's Disease Therapeutics Market: Market Dynamics
Global Parkinson's Disease Therapeutics Market: Market Dynamics

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch Competitive Strategic Window:

The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

360iResearch FPNV Positioning Matrix:

The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Parkinson's Disease Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Company Usability Profiles:

The Parkinson's Disease Therapeutics Market is highly competitive and characterized by the presence of a large number of international and regional players in the market. The market has witnessed increased competition between vendors based on the pricing model, technology differentiation, brand name, quality of service, price differentiation, and technical expertise.

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Parkinson's Disease Therapeutics Market, including Abbvie, Inc., ACADIA Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies, Inc., Boehringer Ingelheim International GmbH, Cipla, Inc., Daiichi Sankyo Company, H. Lundbeck A/S, Mylan N.V., Novartis AG, Orion Corporation, Par Pharmaceutical by Endo International PLC, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and WOCKHARDT.

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & Coverage
    3. Years Considered for the Study
    4. Currency & Pricing
    5. Language
    6. Stakeholders
  2. Research Methodology
    1. Research Process
      1. Define: Research Objective
      2. Determine: Research Design
      3. Prepare: Research Instrument
      4. Collect: Data Source
      5. Analyze: Data Interpretation
      6. Formulate: Data Verification
      7. Publish: Research Report
      8. Repeat: Report Update
    2. Research Execution
      1. Initiation: Research Process
      2. Planning: Develop Research Plan
      3. Execution: Conduct Research
      4. Verification: Finding & Analysis
      5. Publication: Research Report
    3. Research Outcome
  3. Executive Summary
    1. Market Outlook
    2. Type Outlook
    3. Drug Class Outlook
    4. Distribution Channel Outlook
    5. End Use Outlook
    6. Geography Outlook
    7. Competitor Outlook
  4. Market Overview
    1. Introduction
    2. Parkinson's Disease Therapeutics Market, By Geography
  5. Market Dynamics
    1. Introduction
    2. Drivers
      1. Growing aging population and the associated Increase in the prevalence of Parkinson’s disease
      2. Development of new therapies and minimally invasive new devices
    3. Restraints
      1. Availability of alternative treatments
    4. Opportunities
      1. Increasing pace of R&D by the government in the U.S., the UK, and other countries for Parkinson's disease management
      2. Strong drug pipeline under clinical research
      3. Potential for pharmaceutical companies due to patent expiry
    5. Challenges
      1. Sales erosion due to expiry of patents
  6. Market Insights
    1. Porters Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    2. Cumulative Impact of COVID-19
    3. Client Customizations
  7. Global Parkinson's Disease Therapeutics Market, By Type
    1. Introduction
    2. Intestinal Infusion
    3. Oral
    4. Subcutaneous
    5. Transdermal
  8. Global Parkinson's Disease Therapeutics Market, By Drug Class
    1. Introduction
    2. Anticholinergic
    3. Carbidopa/Levodopa
    4. COMT Inhibitor
    5. Dopamine Receptor Agonist
    6. MAO Inhibitor
  9. Global Parkinson's Disease Therapeutics Market, By Distribution Channel
    1. Introduction
    2. Hospital Pharmacy
    3. Online Pharmacy
    4. Retailer Pharmacy
  10. Global Parkinson's Disease Therapeutics Market, By End Use
    1. Introduction
    2. Clinic
    3. Hospital
  11. Americas Parkinson's Disease Therapeutics Market
    1. Introduction
    2. Argentina
    3. Brazil
    4. Canada
    5. Mexico
    6. United States
  12. Asia-Pacific Parkinson's Disease Therapeutics Market
    1. Introduction
    2. Australia
    3. China
    4. India
    5. Indonesia
    6. Japan
    7. Malaysia
    8. Philippines
    9. South Korea
    10. Thailand
  13. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market
    1. Introduction
    2. France
    3. Germany
    4. Italy
    5. Netherlands
    6. Qatar
    7. Russia
    8. Saudi Arabia
    9. South Africa
    10. Spain
    11. United Arab Emirates
    12. United Kingdom
  14. 360iResearch Competitive Strategic Window
    1. Introduction
    2. 360iResearch Competitive Strategic Window, by Type
    3. 360iResearch Competitive Strategic Window, by Drug Class
    4. 360iResearch Competitive Strategic Window, by Distribution Channel
    5. 360iResearch Competitive Strategic Window, by End Use
    6. 360iResearch Competitive Strategic Window, by Geography
  15. Competitive Landscape
    1. 360iResearch FPNV Positioning Matrix
      1. Quadrants
      2. Business Strategy
      3. Product Satisfaction
    2. 360iResearch Market Ranking Analysis
    3. 360iResearch Market Share Analysis
    4. 360iResearch Competitive Scenario
      1. Merger & Acquisition
      2. Agreement, Collaboration, & Partnership
      3. New Product Launch & Enhancement
      4. Investment & Funding
      5. Award, Recognition, & Expansion
  16. Company Usability Profiles
    1. Abbvie, Inc.
    2. ACADIA Pharmaceuticals, Inc.
    3. Amneal Pharmaceuticals, Inc.
    4. Apotex, Inc.
    5. Bausch Health Companies, Inc.
    6. Boehringer Ingelheim International GmbH
    7. Cipla, Inc.
    8. Daiichi Sankyo Company
    9. H. Lundbeck A/S
    10. Mylan N.V.
    11. Novartis AG
    12. Orion Corporation
    13. Par Pharmaceutical by Endo International PLC
    14. Sun Pharmaceutical Industries Limited
    15. Teva Pharmaceutical Industries Ltd.
    16. UCB S.A.
    17. WOCKHARDT
  17. Appendix
    1. Discussion Guide
    2. Edition Details
    3. License Details
    4. Pricing Details

List of Tables

  1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2025 (USD MILLION)
  2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  21. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  22. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  23. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  24. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  25. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  26. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  27. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  28. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  29. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  30. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  31. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  32. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  33. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  34. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  35. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  36. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  37. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  38. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  39. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  40. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  41. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  42. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  43. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  44. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  45. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  46. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  47. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  48. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  49. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  50. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  51. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  52. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  53. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  54. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  55. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  56. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  57. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  58. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  59. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  60. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  61. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  62. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  63. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  64. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  65. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  66. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  67. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  68. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  69. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  70. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  71. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  72. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  73. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  74. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  75. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  76. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  77. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  78. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  79. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  80. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  81. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  82. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  83. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  84. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  85. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  86. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  87. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  88. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  89. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  90. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  91. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  92. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  93. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  94. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  95. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  96. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  97. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  98. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  99. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  100. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  101. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  102. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  103. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  104. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  105. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  106. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  107. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  108. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  109. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  110. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  111. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  112. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  113. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  114. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  115. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  116. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  117. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  118. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  119. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  120. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  121. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  122. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  123. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  124. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  125. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  126. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  127. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  128. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  129. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  130. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  131. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  132. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  133. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  134. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  135. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2017-2025 (USD MILLION)
  136. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: SCORES
  137. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: BUSINESS STRATEGY
  138. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PRODUCT SATISFACTION
  139. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RANKING
  140. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: MERGER & ACQUISITION
  141. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  142. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  143. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: INVESTMENT & FUNDING
  144. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  145. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: EDITION DETAILS
  146. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: LICENSE DETAILS
  147. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PRICING DETAILS

List of Figures

  1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH PROCESS
  2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH EXECUTION
  3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2019 VS 2025 (USD MILLION)
  4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
  5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
  6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019 VS 2025 (USD MILLION)
  7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2019 VS 2025 (USD MILLION)
  8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  9. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, BY TYPE
  10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2017-2025 (USD MILLION)
  11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: MARKET DYNAMICS
  13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
  15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
  16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019 VS 2025 (USD MILLION)
  17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2019 VS 2025 (USD MILLION)
  18. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2025 (USD MILLION)
  19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 (USD MILLION)
  20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 (USD MILLION)
  21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2025 (USD MILLION)
  22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
  24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS

SELECT LICENSE TYPE

Enterprise User License $5949
Corporate User License $4949
Single User License $3949